Clinical Trials
708 trialsTRIDENT-1
Turning Point Therapeutics, Inc.
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)
UNICANCER
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie
STELLAR-002
Exelixis
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
OSIREAL
AstraZeneca
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
National Cancer Institute (NCI)
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
BeOne Medicines
NAPISTAR1-01
Tubulis GmbH
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
National Cancer Institute (NCI)
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
National Institutes of Health Clinical Center (CC)
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
AbbVie
LIBRA
AstraZeneca
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
GlaxoSmithKline
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
Novartis
IMMUNOLUNG
Institut Paoli-Calmettes
MK-3475-U01
Merck Sharp & Dohme LLC
RAINFOL-01
Genmab
EVEREST-2
A2 Biotherapeutics Inc.
INTerpath-002
Merck Sharp & Dohme LLC
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
KANDLELIT-004
Merck Sharp & Dohme LLC
SAINT
Northwestern University
MK-3475-01G
Merck Sharp & Dohme LLC
MK-3475-01H
Merck Sharp & Dohme LLC
MK-3475-01I
Merck Sharp & Dohme LLC
MK-3475-01E
Merck Sharp & Dohme LLC
A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
Bristol-Myers Squibb
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
Dizal Pharmaceuticals
KANDLELIT-007
Merck Sharp & Dohme LLC
INTerpath-13
Merck Sharp & Dohme LLC
MK-6070-003
Merck Sharp & Dohme LLC
DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer
NYU Langone Health
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Hoffmann-La Roche
MK-3475-01F
Merck Sharp & Dohme LLC
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
Merus B.V.
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
Guangdong Association of Clinical Trials
INTerpath-014
Merck Sharp & Dohme LLC
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
National Institutes of Health Clinical Center (CC)
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
National Institutes of Health Clinical Center (CC)
Bio-lung
University Hospital, Lille
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
NAUTIKA1
Genentech, Inc.
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
National Institutes of Health Clinical Center (CC)
NeoCOAST-2
AstraZeneca
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen